

## The SARS-CoV-2 pandemic has affected many people, including health care workers and claimed the lives of more than 3 million.


Pall Breathing System
Filters (Ultipor® 25,
Ultipor® 50, Ultipor® 100 and
BB50TE) have been shown
in laboratory testing to
retain aerosolized
SARS-CoV-2 viruses at
> 99.999 % efficiency<sup>1</sup>



Clinical studies have previously shown that Pall Breathing System Filters meet the highest performance standards in the prevention of cross contamination<sup>2,3</sup>



## We can confirm:



Pall Breathing System Filters have been shown to retain > 99.999 % of the aerosolized SARS-CoV-2 and are expected to form an effective barrier against airborne virus contamination from ventilated patient's exhaled breath<sup>4</sup>

- Pall SLS Technical Reports 2021 This claim has been cleared for Europe under CE mark. It has not been cleared by the FDA
- Hübner et al. (2011); GMS Krankenhaushygiene Interdisziplinär Vol. 6(1) ISSN 18635245
- Dubler et al. (2016); Acta Anaesthesiologica Scandinavica Oct;60(9):1251-60
- <sup>4</sup> Leung NH, Chu DK, Shiu EY, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks (Nat Med. 2020;26:676–680

Visit us on the Web at www.pall.com/medical Contact us at www.pall.com/contact

© Copyright 2021, Pall Corporation. Pall, (ALL), and Ultipor are trademarks of Pall Corporation.

® Indicates a trademark registered in the USA.
210511.1AEU
09/2021